Masahiro Tabata

5.9k total citations
225 papers, 4.5k citations indexed

About

Masahiro Tabata is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Masahiro Tabata has authored 225 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 161 papers in Oncology, 156 papers in Pulmonary and Respiratory Medicine and 51 papers in Molecular Biology. Recurrent topics in Masahiro Tabata's work include Lung Cancer Treatments and Mutations (119 papers), Lung Cancer Research Studies (97 papers) and Neuroendocrine Tumor Research Advances (35 papers). Masahiro Tabata is often cited by papers focused on Lung Cancer Treatments and Mutations (119 papers), Lung Cancer Research Studies (97 papers) and Neuroendocrine Tumor Research Advances (35 papers). Masahiro Tabata collaborates with scholars based in Japan, United States and Greece. Masahiro Tabata's co-authors include Katsuyuki Kiura, Mitsune Tanimoto, Hiroshi Ueoka, Katsuyuki Hotta, Nagio Takigawa, Keitaro Matsuo, Keiichi Fujiwara, Eiki Ichihara, Takuo Shibayama and Yoshiro Fujiwara and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Masahiro Tabata

213 papers receiving 4.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Masahiro Tabata Japan 35 2.9k 2.9k 1.3k 606 465 225 4.5k
Nagio Takigawa Japan 41 2.9k 1.0× 2.9k 1.0× 1.9k 1.5× 749 1.2× 432 0.9× 304 5.2k
Radj Gervais France 24 4.0k 1.4× 3.7k 1.3× 1.1k 0.8× 617 1.0× 246 0.5× 83 5.2k
Shinji Atagi Japan 36 3.3k 1.1× 3.2k 1.1× 819 0.6× 430 0.7× 491 1.1× 182 4.5k
Hiroaki Akamatsu Japan 28 3.8k 1.3× 3.5k 1.2× 1.2k 1.0× 1.1k 1.8× 309 0.7× 144 5.1k
Paolo Maione Italy 31 2.0k 0.7× 2.2k 0.8× 1.1k 0.9× 452 0.7× 233 0.5× 138 3.6k
Nick Thatcher United Kingdom 34 3.9k 1.3× 4.0k 1.4× 1.5k 1.2× 810 1.3× 434 0.9× 117 5.7k
Jens Benn Sørensen Denmark 35 2.4k 0.8× 1.9k 0.6× 932 0.7× 487 0.8× 320 0.7× 143 4.0k
Petr Zatloukal Czechia 33 3.4k 1.2× 3.7k 1.3× 1.6k 1.3× 603 1.0× 410 0.9× 87 5.7k
Shunichi Sugawara Japan 36 3.5k 1.2× 4.2k 1.5× 1.1k 0.9× 548 0.9× 507 1.1× 209 5.4k
Adolfo Favaretto Italy 31 2.2k 0.7× 1.7k 0.6× 780 0.6× 357 0.6× 371 0.8× 136 3.7k

Countries citing papers authored by Masahiro Tabata

Since Specialization
Citations

This map shows the geographic impact of Masahiro Tabata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masahiro Tabata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masahiro Tabata more than expected).

Fields of papers citing papers by Masahiro Tabata

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masahiro Tabata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masahiro Tabata. The network helps show where Masahiro Tabata may publish in the future.

Co-authorship network of co-authors of Masahiro Tabata

This figure shows the co-authorship network connecting the top 25 collaborators of Masahiro Tabata. A scholar is included among the top collaborators of Masahiro Tabata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masahiro Tabata. Masahiro Tabata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tomida, Shuta, Naofumi Hara, Hirofumi Inoue, et al.. (2025). Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation. Molecular Cancer Therapeutics. 24(11). 1763–1774.
2.
Nishi, Tatsuya, Ayako Morita, Naofumi Hara, et al.. (2025). Efficacy of amivantamab, a bi-specific antibody targeting EGFR and MET, in ALK-rearranged non-small-cell lung cancer cell lines. Lung Cancer. 201. 108415–108415. 1 indexed citations
3.
Ninomiya, Kiichiro, Daisuke Ennishi, Kunio Okamoto, et al.. (2024). Response to Imatinib in a Patient With Gastric Adenocarcinoma With KIT Q556_K558 In-Frame Deletion: A Case Report. JCO Precision Oncology. 8(8). e2400228–e2400228.
4.
Hasebe, Shinji, Tomomi Fujii, Taketsugu Fujibuchi, et al.. (2023). Treatments and prognostic factors for bone and soft tissue sarcoma in non-urban areas in Japan. International Journal of Clinical Oncology. 29(3). 345–353. 2 indexed citations
5.
Kubo, Toshio, Eiki Ichihara, Daijiro Harada, et al.. (2023). Efficacy of immune checkpoint inhibitor monotherapy in elderly patients with non-small-cell lung cancer. Respiratory Investigation. 61(5). 643–650. 3 indexed citations
6.
Yamada, Yuto, Masaki Fujiwara, Shin‐ichiro Inoue, et al.. (2023). Perceptions toward issues in cancer care for people with mental illness among psychiatric care providers: A questionnaire study. Psycho-Oncology. 32(7). 1022–1029.
7.
Katayama, Hideki, Masahiro Tabata, Haruhito Kamei, Yusuke Mimura, & Yoshinobu Maeda. (2023). Relationship Between Corticosteroid Administration and Survival Period in Terminal Cancer Patients. Journal of Palliative Care. 39(3). 238–243. 1 indexed citations
8.
Tahara, Makoto, Tatsunori Shimoi, Satoshi Nishiwaki, et al.. (2023). Phase II trial of dabrafenib and trametinib in patients with BRAFV600E/R or non-BRAFV600 mutated advanced solid tumors: Results from the BELIEVE trial (NCCH1901).. Journal of Clinical Oncology. 41(16_suppl). 3096–3096. 1 indexed citations
9.
Kano, Hirohisa, Eiki Ichihara, Hiromi Watanabe, et al.. (2021). SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1- , or EGFR -altered Non–small Cell Lung Cancer. Molecular Cancer Therapeutics. 20(9). 1653–1662. 13 indexed citations
10.
Katayama, Hideki, Masahiro Tabata, Toshio Kubo, et al.. (2020). Demand for weekend outpatient chemotherapy among patients with cancer in Japan. Supportive Care in Cancer. 29(3). 1287–1291. 6 indexed citations
11.
Nishimori, Hisakazu, et al.. (2013). Risk factor for occlusion of central venous access port system in colon cancer patients. Palliative Care Research. 8(1). 135–141. 1 indexed citations
12.
Ichihara, Eiki, Kadoaki Ohashi, Nagio Takigawa, et al.. (2008). Emergence of the EGFR T790M mutation in a lung adenocarcinoma cell line after vandetanib treatment. Cancer Research. 68. 678–678.
13.
Uchida, Akiko, Seiki Hirano, Hiroyuki Kitao, et al.. (2007). Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib‐resistance in cells carrying EGFR mutation. Cancer Science. 98(3). 357–363. 41 indexed citations
14.
Tokumo, Masaki, Shinichi Toyooka, Shuji Ichihara, et al.. (2006). Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer. Lung Cancer. 53(1). 117–121. 48 indexed citations
15.
Hisamoto, Akiko, Eisei Kondo, Katsuyuki Kiura, et al.. (2005). Profile of phospho-proteins according to LKB1 gene status in lung cancer cells. Cancer Research. 65. 1348–1348. 1 indexed citations
16.
Tokumo, Masaki, Shinichi Toyooka, Katsuyuki Kiura, et al.. (2005). The relationship between epidermal growth factor receptor(EGFR) mutations and clinico-pathological features in non-small cell lung cancers. Cancer Research. 65. 393–393. 2 indexed citations
17.
Tada, Atsuhiko, Hiroshi Ueoka, Katsuyuki Kiura, et al.. (2002). [Combination chemotherapy with carboplatin and etoposide for elderly patients aged 76 years or older with small cell lung cancer].. PubMed. 29(5). 751–6. 1 indexed citations
18.
Takata, Ichiro, Yoshihiko Segawa, Masahiro Tabata, et al.. (2001). Small Bowel Metastasis From Large Cell Carcinoma of the Lung: Report of Two Cases.. Haigan. 41(7). 783–785. 1 indexed citations
19.
20.
Kiura, Katsuyuki, T Ohnoshi, Masahiro Tabata, Takuo Shibayama, & Ikuro Kimura. (1993). Establishment of an adriamycin-resistant subline of human small cell lung cancer showing multifactorial mechanisms of resistance.. Okayama University Scientific Achievement Repository (Okayama University). 47(3). 191–7. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nagio Takigawa Breakdown of academic impact, for papers by Radj Gervais Breakdown of academic impact, for papers by Shinji Atagi Breakdown of academic impact, for papers by Hiroaki Akamatsu Breakdown of academic impact, for papers by Paolo Maione Breakdown of academic impact, for papers by Nick Thatcher Breakdown of academic impact, for papers by Jens Benn Sørensen Breakdown of academic impact, for papers by Petr Zatloukal Breakdown of academic impact, for papers by Shunichi Sugawara Breakdown of academic impact, for papers by Adolfo Favaretto
Rankless by CCL
2026